MSI-H tumors often have a high mutational burden, which means they produce many abnormal proteins that can be recognized by the immune system. This makes them more likely to respond to immunotherapy, which works by enhancing the body's immune response against cancer cells. Clinical trials have shown that patients with MSI-H tumors have higher response rates to checkpoint inhibitors, leading to improved outcomes.
